SCHEMBL4283449

SCHEMBL4283449

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2C(F)(F)F)c2c1CN(S(=O)(=O)c1ccccc1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.42
DRD3 P35462 3/20 0.40
HRH3 Q9Y5N1 1/20 0.39
HTT P42858 1/20 0.38
POLB P06746 1/20 0.38
PTGDR Q13258 3/20 0.37
KMT2A Q03164 2/20 0.37
HTR6 P50406 1/20 0.37
MEN1 O00255 1/20 0.37
PDK2 Q15119 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
P2RY12 Q9H244 1/20 0.36
ATM Q13315 1/20 0.35
INSR P06213 1/20 0.35
ALK Q9UM73 1/20 0.35
KIT P10721 1/20 0.35
FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282875 0.93 IGF1R (0.45) IGF1RHTTPOLBKMT2AHTR6
SCHEMBL1894264 0.86 IGF1R (0.43) IGF1RDRD3HRH3HTTPOLB
SCHEMBL15338600 0.84 ALK (0.42) HTTPDK2MAPTALK
SCHEMBL1890266 0.83 SIRT6 (0.42) IGF1RHTTPOLBPTGDRKMT2A
SCHEMBL4281362 0.82 ALK (0.39) HTTKMT2AMEN1PDK2MAPT
SCHEMBL4283455 0.82 FLT3 (0.36) IGF1RHTR6INSRALKKIT
SCHEMBL4285119 0.81 ALK (0.39) IGF1RINSRALKKITFLT3
Hydrochloric Acid SCHEMBL4285112 0.81 ALK (0.38) IGF1RINSRALKKITFLT3
SCHEMBL4287268 0.80 TAAR1 (0.42) IGF1RKMT2AMEN1KDM4EMAPT
SCHEMBL1889132 0.80 IGF1R (0.47) IGF1RHTTPOLBKMT2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 IGF1R 530/4885DRD3 2957/4885HRH3 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.